

Human TFF1 Protein

Cat. No. TFF-HM201



Description

Source	Recombinant Human TFF1 Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Glu25-Phe84.
Accession	P04155
Molecular Weight	The protein has a predicted MW of 33.3 kDa. Due to glycosylation, the protein migrates to 40-45 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Breast cancer (BC) is the most common cancer in women and the second leading cause of their cancer death. Establishing an accurate BC prognosis is very difficult because of its heterogeneity. Elevated TFF1 levels in serum were associated with development of BC, TFF1 expression was upregulated in BC compared to the healthy breast tissue. That expression of TFF1 was related to ER status of BC and that expression of TFF1 was lower in TNBC than in non-TNBC.

Assay Data


Tris-Bis PAGE



Human TFF1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data



The purity of Human TFF1 is greater than 95% as determined by SEC-HPLC.